MitoQ ( DrugBank: - )

3 diseases

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00329056 (ClinicalTrials.gov)	May 2006	22/5/2006	A Trial of MitoQ for the Treatment of People With Parkinson's Disease	A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's Disease	Parkinson's Disease	Drug: MitoQ	Antipodean Pharmaceuticals, Inc.	NULL	Completed	30 Years	N/A	Both	128	Phase 2	Australia;New Zealand

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04267926 (ClinicalTrials.gov)	April 1, 2020	11/2/2020	MitoQ for Fatigue in Multiple Sclerosis (MS)	MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial	Multiple Sclerosis;Fatigue	Drug: 20 mg MitoQ;Drug: Placebo;Drug: 40mg of MitoQ	VA Office of Research and Development	NULL	Recruiting	18 Years	70 Years	All	60	Phase 1/Phase 2	United States
2	NCT03166800 (ClinicalTrials.gov)	September 15, 2018	23/5/2017	MitoQ for Fatigue in Multiple Sclerosis	MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial	Multiple Sclerosis;Fatigue	Drug: Mitoquinone	Oregon Health and Science University	MitoQ Ltd	Completed	18 Years	70 Years	All	9	Phase 1/Phase 2	United States

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05539625 (ClinicalTrials.gov)	September 2022	4/8/2022	Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis	Mitochondrial Antioxidant Therapy to Resolve Inflammation in Ulcerative Colitis (Mini-MARVEL): A Phase 2b Feasibility Randomised Placebo Controlled Trial of Oral MitoQ in Mild-tomoderately Active Paediatric UC	Ulcerative Colitis	Dietary Supplement: MitoQ;Other: Placebo	University of Edinburgh	The Jon Moulton Charity Trust;MitoQ	Not yet recruiting	6 Years	17 Years	All	120	Phase 2	NULL
2	NCT04276740 (ClinicalTrials.gov)	May 31, 2022	12/2/2020	MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis	Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis (MARVEL): A Randomised Placebo-controlled Trial on Oral MitoQ in Moderate UC	Ulcerative Colitis Flare	Dietary Supplement: MitoQ;Other: Placebo	University of Edinburgh	JP Moulton Charitable Foundation;MitoQ	Not yet recruiting	18 Years	N/A	All	206	Phase 2	NULL